Sickle Cell Anemia Diagnostic Blood Test at Dr. Essa Lab

Sickle Cell at Dr. Essa Lab

The Sickle Cell test at Dr. Essa Lab is a highly specialized hematological investigation designed to detect the presence of abnormal hemoglobin S (HbS) in the blood. Hemoglobin is the vital, iron-rich protein found within red blood cells (RBCs) responsible for transporting oxygen from the lungs to the rest of the body. In healthy individuals, the predominant form of this protein is Hemoglobin A (HbA), which allows red blood cells to maintain a flexible, biconcave disc shape. This shape is crucial as it enables the cells to squeeze easily through the narrowest capillaries to deliver oxygen to tissues. However, individuals with specific genetic mutations produce an abnormal variant known as Hemoglobin S. Under conditions of low oxygen tension, dehydration, or acidosis, HbS molecules polymerize into rigid, rod-like structures. This polymerization distorts the red blood cells into a rigid, crescent, or sickle shape, leading to premature cell destruction (hemolysis) and microvascular occlusion.

Understanding the clinical significance of this test requires an appreciation of its diagnostic value. The Sickle Cell test at Dr. Essa Lab serves as a primary screening tool to identify individuals who carry the sickle cell gene. This includes both those with Sickle Cell Trait (heterozygous carriers who inherit one abnormal gene, HbAS) and those with Sickle Cell Disease (homozygous individuals who inherit two abnormal genes, HbSS). Differentiating between these states is of paramount clinical importance. While individuals with the trait are typically asymptomatic and lead normal lives, they can pass the gene to their offspring. Conversely, individuals with Sickle Cell Disease suffer from chronic hemolytic anemia, frequent painful vaso-occlusive crises, increased susceptibility to severe infections, and progressive organ damage. By utilizing advanced diagnostic methodologies, Dr. Essa Lab provides accurate, reliable, and timely results that are essential for early intervention, genetic counseling, and the management of this hereditary blood disorder.

The technology utilized at Dr. Essa Lab for this investigation involves highly sensitive and specific laboratory techniques. The primary screening method is the Hemoglobin Solubility Test. This method relies on the unique physical properties of Hemoglobin S when exposed to a reducing agent, such as sodium hydrosulfite. In this test, whole blood is mixed with a phosphate buffer solution containing the reducing agent. Under these conditions, HbS precipitates, rendering the solution turbid and cloudy, whereas normal hemoglobins remain soluble and the solution stays clear. While the solubility test is an excellent screening mechanism, any positive result is systematically followed by confirmatory testing, such as Hemoglobin Electrophoresis or High-Performance Liquid Chromatography (HPLC). These advanced techniques separate different hemoglobin variants based on their electrical charge or molecular size, allowing for the precise quantification of HbS, HbA, and other variants like Hemoglobin F (fetal hemoglobin), thereby ensuring an absolute and definitive diagnosis.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the utmost accuracy of the Sickle Cell test results at Dr. Essa Lab, patients are advised to adhere to specific preparation guidelines. While the test itself does not require strict fasting, maintaining optimal hydration is highly recommended. Drinking plenty of water before the blood draw helps ensure that the veins are well-filled, making the venipuncture process smoother and more comfortable. Patients should inform the laboratory staff and their referring physician about all medications, vitamins, and dietary supplements they are currently taking, as certain substances can theoretically interfere with laboratory assays.

The most critical preparation factor is the disclosure of recent blood transfusions. If a patient has received a blood transfusion within the past three to four months, they must inform the healthcare team. Transfused blood contains normal donor red blood cells (primarily HbA), which can temporarily dilute the patient’s own abnormal red blood cells (HbS). This dilution can lead to a false-negative screening result or an inaccurate quantification of hemoglobin variants during confirmatory electrophoresis. In such cases, physicians may recommend delaying the test until the transfused cells have cleared from the patient’s circulation.

During the Procedure

The collection of the blood sample for the Sickle Cell test at Dr. Essa Lab follows a standardized, sterile venipuncture protocol to guarantee patient safety and sample integrity. Upon arriving at the blood collection area, the patient is comfortably seated. A certified phlebotomist will verify the patient’s identity and explain the steps of the procedure. The phlebotomist then inspects the patient’s arm to locate a suitable vein, typically in the antecubital fossa (the crook of the elbow). Once a vein is selected, the skin over the site is thoroughly cleansed with an antiseptic solution, such as isopropyl alcohol, and allowed to air dry to prevent contamination and minimize discomfort.

A sterile tourniquet is applied a few inches above the selected site to temporarily restrict venous blood flow, making the vein more prominent and easier to access. The phlebotomist then gently inserts a sterile, single-use needle into the vein. A small volume of blood is drawn into a vacuum tube containing an anticoagulant, typically Ethylenediaminetetraacetic acid (EDTA), which prevents the blood from clotting and preserves the cellular structure of the red blood cells. The patient may feel a brief, mild pinch or stinging sensation as the needle enters the skin. Once the collection is complete, the needle is carefully withdrawn, and immediate pressure is applied to the puncture site with a sterile gauze pad to stop any bleeding. A small adhesive bandage is then applied. The entire process takes less than five minutes, and patients can immediately resume their daily activities.

When is a Sickle Cell Test Performed?

Screening for Sickle Cell Trait (HbAS)

Physicians frequently request a Sickle Cell test to screen individuals for the Sickle Cell Trait, especially those with a family history of the disorder or those belonging to high-risk ethnic groups. Identifying carriers is crucial for family planning and genetic counseling. Because carriers of the trait are usually asymptomatic, many are unaware of their genetic status. Testing allows prospective parents to understand the risk of passing the sickle cell gene to their children, enabling informed reproductive choices and early preparation for potential neonatal care.

Evaluating Symptoms of Sickle Cell Anemia (HbSS)

When a patient presents with clinical signs suggestive of sickle cell anemia, a diagnostic test is urgently required. These symptoms often manifest in early childhood and include recurrent episodes of severe, debilitating pain (vaso-occlusive crises) in the bones, joints, abdomen, or chest. Other symptoms include chronic fatigue, pale skin (pallor), jaundice (yellowing of the skin and eyes due to rapid RBC breakdown), and dactylitis (painful swelling of the hands and feet in infants). The test helps confirm whether these symptoms are caused by homozygous sickle cell disease.

Prenatal and Newborn Screening

Newborn screening is one of the most vital applications of the Sickle Cell test. In many clinical settings, this test is performed routinely shortly after birth to identify affected infants immediately. Early diagnosis is lifesaving, as it allows healthcare providers to initiate prophylactic interventions, such as daily penicillin therapy and a structured vaccination schedule, to protect the infant from life-threatening bacterial infections like pneumococcal sepsis, which poses a severe threat to young children with functional asplenia.

Investigating Unexplained Hemolytic Anemia

In patients presenting with unexplained, chronic hemolytic anemia, the Sickle Cell test is an essential component of the diagnostic workup. Hemolytic anemia occurs when red blood cells are destroyed faster than the bone marrow can replace them. Clinical indicators include elevated indirect bilirubin, high lactate dehydrogenase (LDH) levels, a low haptoglobin level, and an elevated reticulocyte count. Performing the test helps determine if an underlying hemoglobinopathy, specifically the presence of HbS, is the primary driver of the accelerated red cell destruction.

Pre-operative Assessment in High-Risk Populations

Surgeons and anesthesiologists often request a Sickle Cell test prior to major surgical procedures for patients from high-risk demographics who do not have a documented testing history. Surgical procedures, anesthesia, and post-operative recovery can expose patients to physiological stressors such as hypoxia, hypothermia, dehydration, and acidosis. In individuals with undiagnosed sickle cell disease or severe trait, these conditions can precipitate a sudden, life-threatening sickling crisis. Pre-operative identification allows the medical team to implement protective protocols to maintain optimal oxygenation and hydration.

What Does a Sickle Cell Test Detect?

The Sickle Cell test and its associated confirmatory panels at Dr. Essa Lab are designed to detect a wide array of pathological states, physiological changes, and specific hemoglobin variants. The primary and most critical finding is the presence or absence of Hemoglobin S (HbS) within the patient’s red blood cells. In a healthy individual, the test will detect only normal adult hemoglobin (HbA) and trace amounts of Hemoglobin A2 and Fetal Hemoglobin (HbF). The detection of HbS indicates that the patient carries at least one copy of the mutated beta-globin gene.

Beyond the simple presence of HbS, the comprehensive testing process detects the specific genetic dosage of the mutation. It can distinguish between Sickle Cell Trait (HbAS), where the percentage of HbS is typically lower than that of HbA, and Sickle Cell Disease (HbSS), where HbS is the dominant hemoglobin and HbA is entirely absent. The test also detects other complex hemoglobinopathies that interact with the sickle gene, such as Hemoglobin SC disease (where the patient inherits one HbS gene and one HbC gene) and Sickle Beta-Thalassemia (where the patient inherits one HbS gene and a gene for beta-thalassemia, leading to reduced or absent production of normal beta chains).

Furthermore, the laboratory evaluation detects secondary hematological markers associated with the disease. On a peripheral blood smear, the test detects characteristic morphological abnormalities of the red blood cells, including classic sickle-shaped cells (drepanocytes), target cells (codocytes), and Howell-Jolly bodies, which are nuclear remnants in circulating erythrocytes indicating that the spleen is no longer filtering blood effectively. The test also detects signs of active bone marrow compensation, such as a high reticulocyte count (immature red blood cells), which indicates that the body is attempting to replace the rapidly destroyed sickled cells. In summary, the test detects:

• The presence of abnormal Hemoglobin S (HbS) in the bloodstream.
• Differentiating between heterozygous Sickle Cell Trait (HbAS) and homozygous Sickle Cell Disease (HbSS).
• Co-inheritance of other abnormal hemoglobins, such as Hemoglobin C (resulting in HbSC disease).
• Interaction with thalassemia genes, specifically Sickle Beta-Plus or Beta-Zero Thalassemia.
• The percentage of Fetal Hemoglobin (HbF), which serves as a protective factor against sickling.
• Turbidity in the solubility assay, indicating the precipitation of insoluble HbS.
• The presence of classic sickle-shaped red blood cells (drepanocytes) on a peripheral blood smear.
• Target cells (codocytes) associated with hemoglobinopathies and splenomegaly.
• Howell-Jolly bodies, indicating functional asplenia or splenic atrophy.
• Polychromasia, reflecting an increased population of young, immature red blood cells.
• Reticulocytosis, confirming an accelerated erythropoietic response to chronic hemolysis.
• Anisocytosis, indicating a high variation in the size of the red blood cells.
• Poikilocytosis, demonstrating a wide variety of abnormal red blood cell shapes.
• Nucleated red blood cells, which may enter circulation during severe hemolytic stress.
• Decreased total hemoglobin concentration, confirming the severity of the anemia.
• Decreased hematocrit levels, reflecting a lower volume of red blood cells in the blood.
• Elevated levels of indirect bilirubin, a byproduct of rapid red blood cell breakdown.
• Increased serum lactate dehydrogenase (LDH) due to ongoing intravascular hemolysis.
• Markedly decreased or undetectable levels of serum haptoglobin, which binds free hemoglobin.
• Reactive leukocytosis, a common finding in sickle cell disease reflecting chronic inflammation.
• Reactive thrombocytosis, often observed in patients with functional or surgical asplenia.

Turnaround Time and Report Access at Dr. Essa Lab

Dr. Essa Lab is widely recognized across Karachi and the wider region of Pakistan for its commitment to clinical excellence, rapid turnaround times, and seamless patient care. For a routine Sickle Cell screening test (such as the Hemoglobin Solubility Test), results are typically processed and verified within 24 hours of sample collection. If the initial screening is positive, confirmatory testing via Hemoglobin Electrophoresis or HPLC is initiated immediately. These advanced confirmatory procedures may require an additional 24 to 48 hours to ensure absolute precision and detailed quantification of the hemoglobin variants.

Once the diagnostic reports are finalized, they undergo a rigorous multi-step verification process by qualified hematologists and consultant pathologists at Dr. Essa Lab. Patients and referring physicians are notified immediately via an automated SMS alert. Reports can be accessed easily and securely online through the official Dr. Essa Lab web portal or the dedicated mobile application, allowing patients to download, print, or share their results directly with their healthcare providers. Physical copies of the reports are also available for collection at any of the numerous convenient Dr. Essa Lab collection centers located throughout the city.

Sickle Cell Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Hemoglobin S (HbS) Percentage	0% (Absent)	30% – 45% (Sickle Cell Trait); >80% (Sickle Cell Disease)
Hemoglobin A (HbA) Percentage	95% – 98% (Normal adult hemoglobin)	Decreased (in trait or HbS-beta+ thal); 0% (Absent in homozygous HbSS)
Hemoglobin F (HbF) Percentage	<1% – 2% (In adults)	Elevated (5% – 20% or higher in Sickle Cell Disease as a compensatory mechanism)
Red Blood Cell Morphology	Normal biconcave discs, uniform size and shape	Presence of sickle cells, target cells, Howell-Jolly bodies, anisopoikilocytosis
Solubility Test Appearance	Clear, transparent solution	Turbid, cloudy, or opaque solution indicating HbS precipitation
Reticulocyte Count	0.5% – 2.5% (Normal red blood cell replacement)	Elevated (5% – 20% or higher, indicating active bone marrow response to hemolysis)
Total Hemoglobin Concentration	12.0 – 16.0 g/dL (Females); 13.5 – 17.5 g/dL (Males)	Decreased (typically 6.0 – 9.0 g/dL in homozygous Sickle Cell Disease)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Sickle Cell?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly trained, certified phlebotomists and medical technologists specializing in hematology.
• Pathologist Supervision: All positive screening tests and confirmatory electrophoresis profiles are reviewed and validated by expert consultant pathologists.
• State-of-the-Art Technology: Dr. Essa Lab utilizes modern, fully automated hematology analyzers and high-precision HPLC systems for accurate hemoglobin typing.
• Rigorous Quality Control: We participate in external quality assurance programs and maintain strict internal quality control protocols to ensure reliable results.
• Convenient Home Sample Collection: Patients can schedule a professional blood draw in the comfort of their homes across Karachi and other major cities.
• Rapid Turnaround Time: We understand the anxiety associated with diagnostic testing and work efficiently to deliver verified results promptly.
• Easy Digital Report Access: Patients can view, download, and share their diagnostic reports securely via our online portal or mobile application.
• Extensive Network: With numerous collection centers, finding a convenient location for your diagnostic needs is simple and accessible.